The U.S. pharmaceutical landscape is evolving rapidly, with new policies targeting drug pricing, supply chain resilience, and health equity. The FDA's new PreCheck program adds another layer, streamlining domestic manufacturing oversight while reinforcing affordability and innovation goals. This blog unpacks what these changes mean for pharma companies, policymakers, and patients alike.